Gan HK - Search Results

1

Assumptions of expected benefits in randomized phase III trials evaluating systemic treatments for cancer.

Gan HK, You B, Pond GR, Chen EX. Gan HK, et al. J Natl Cancer Inst. 2012 Apr 18;104(8):590-8. doi: 10.1093/jnci/djs141. Epub 2012 Apr 6. J Natl Cancer Inst. 2012. PMID: 22491345 Review.

2

Quality of reporting of modern randomized controlled trials in medical oncology: a systematic review.

Péron J, Pond GR, Gan HK, Chen EX, Almufti R, Maillet D, You B. Péron J, et al. Among authors: gan hk. J Natl Cancer Inst. 2012 Jul 3;104(13):982-9. doi: 10.1093/jnci/djs259. Epub 2012 Jul 3. J Natl Cancer Inst. 2012. PMID: 22761273 Review.

3

Adherence to CONSORT adverse event reporting guidelines in randomized clinical trials evaluating systemic cancer therapy: a systematic review.

Péron J, Maillet D, Gan HK, Chen EX, You B. Péron J, et al. Among authors: gan hk. J Clin Oncol. 2013 Nov 1;31(31):3957-63. doi: 10.1200/JCO.2013.49.3981. Epub 2013 Sep 23. J Clin Oncol. 2013. PMID: 24062406 Review.

4

A systematic review of adverse events in randomized trials assessing immune checkpoint inhibitors.

Arnaud-Coffin P, Maillet D, Gan HK, Stelmes JJ, You B, Dalle S, Péron J. Arnaud-Coffin P, et al. Among authors: gan hk. Int J Cancer. 2019 Aug 1;145(3):639-648. doi: 10.1002/ijc.32132. Epub 2019 Feb 4. Int J Cancer. 2019. PMID: 30653255

5

Poor patient-reported outcomes reporting according to CONSORT guidelines in randomized clinical trials evaluating systemic cancer therapy.

Bylicki O, Gan HK, Joly F, Maillet D, You B, Péron J. Bylicki O, et al. Among authors: gan hk. Ann Oncol. 2015 Jan;26(1):231-237. doi: 10.1093/annonc/mdu489. Epub 2014 Oct 29. Ann Oncol. 2015. PMID: 25355720 Free article.

6

The reporting of adverse events in oncology phase III trials: a comparison of the current status versus the expectations of the EORTC members.

Maillet D, Blay JY, You B, Rachdi A, Gan HK, Péron J. Maillet D, et al. Among authors: gan hk. Ann Oncol. 2016 Jan;27(1):192-8. doi: 10.1093/annonc/mdv485. Epub 2015 Oct 19. Ann Oncol. 2016. PMID: 26483049 Free article.

7

Inclusion of elderly patients in oncology clinical trials.

Le Saux O, Falandry C, Gan HK, You B, Freyer G, Péron J. Le Saux O, et al. Among authors: gan hk. Ann Oncol. 2016 Sep;27(9):1799-804. doi: 10.1093/annonc/mdw259. Epub 2016 Jun 29. Ann Oncol. 2016. PMID: 27358382 Free article.

8

Changes in the use of end points in clinical trials for elderly cancer patients over time.

Le Saux O, Falandry C, Gan HK, You B, Freyer G, Péron J. Le Saux O, et al. Among authors: gan hk. Ann Oncol. 2017 Oct 1;28(10):2606-2611. doi: 10.1093/annonc/mdx354. Ann Oncol. 2017. PMID: 28961850 Free article.

9

[Consistency in the analysis and reporting of PEPs in oncology randomized controlled trials from registration to publication: a systematic review].

Boespflug A, Gan H, Chen EX, Pond G, You B. Boespflug A, et al. Bull Cancer. 2012 Oct;99(10):943-52. doi: 10.1684/bdc.2012.1651. Bull Cancer. 2012. PMID: 23034429 Review. French.

10

Randomized phase II trials: inevitable or inadvisable?

Gan HK, Grothey A, Pond GR, Moore MJ, Siu LL, Sargent D. Gan HK, et al. J Clin Oncol. 2010 May 20;28(15):2641-7. doi: 10.1200/JCO.2009.26.3343. Epub 2010 Apr 20. J Clin Oncol. 2010. PMID: 20406933 No abstract available.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

144 results

Search Page

Filters